Radiolabeled Antibodies for Cancer Imaging and Therapy, Methods Mol Biol, vol.907, pp.681-697978, 2012. ,
DOI : 10.1007/978-1-61779-974-7_38
Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-734, 2011. ,
DOI : 10.1038/nrclinonc.2011.160
Antitumor Immunity Induced after ?? Irradiation, Neoplasia, vol.16, issue.4, pp.319-328, 2014. ,
DOI : 10.1016/j.neo.2014.04.002
Radioimmunotherapy of human tumours, Nature Reviews Cancer, vol.9, issue.6, pp.347-360, 2015. ,
DOI : 10.4161/cbt.6.6.4089
Radioimmunoconjugates for the Treatment of Cancer, Seminars in Oncology, vol.41, issue.5, pp.613-622, 2014. ,
DOI : 10.1053/j.seminoncol.2014.07.004
Radioimmunotherapy of B-cell non-Hodgkin???s lymphoma, Frontiers in Oncology, vol.3, p.177, 2013. ,
DOI : 10.3389/fonc.2013.00177
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan, Cancer, vol.23, issue.9, pp.1804-1810, 2007. ,
DOI : 10.1002/cncr.22617
Phase III Trial of Consolidation Therapy With Yttrium-90???Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, Journal of Clinical Oncology, vol.26, issue.32, pp.5156-5164, 2008. ,
DOI : 10.1200/JCO.2008.17.2015
Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria, Journal of Clinical Oncology, vol.32, issue.3, pp.212-218, 2014. ,
DOI : 10.1200/JCO.2013.50.3110
Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin???s Lymphomas, Journal of Clinical Oncology, vol.23, issue.30, pp.7565-7573, 2005. ,
DOI : 10.1200/JCO.2004.00.9217
High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.28, issue.23, pp.3709-3716, 2010. ,
DOI : 10.1200/JCO.2009.27.7863
Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?, Journal of Clinical Oncology, vol.28, issue.18, pp.2944-2946, 2010. ,
DOI : 10.1200/JCO.2009.26.8748
Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumor Biology, vol.32, issue.5, pp.679-688, 2012. ,
DOI : 10.1007/s13277-012-0362-y
213Bi Radioimmunotherapy with an Anti-mCD138 Monoclonal Antibody in a Murine Model of Multiple Myeloma, Journal of Nuclear Medicine, vol.54, issue.9, pp.213-1597, 2013. ,
DOI : 10.2967/jnumed.112.111997
Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy, Nuclear Medicine and Biology, vol.41, pp.30-35008, 2014. ,
DOI : 10.1016/j.nucmedbio.2014.02.008
Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, issue.4, pp.1233-1239, 2002. ,
DOI : 10.14694/EdBook_AM.2014.34.e126
Alpha particles more promising than toxins?, European Journal of Nuclear Medicine and Molecular Imaging, vol.15, issue.12, pp.849-850, 2010. ,
DOI : 10.1007/s00259-010-1421-5
URL : http://doi.org/10.1007/s00259-010-1421-5
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors, Journal of Cancer Research and Therapeutics, vol.5, issue.9, pp.36-40, 2009. ,
DOI : 10.4103/0973-1482.55139
Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy, MIRD Pamphlet No. J Nucl Med, vol.2251, issue.2, pp.311-328, 2010. ,
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, issue.3, pp.453-474, 2009. ,
DOI : 10.1182/blood-2009-07-235358
Acute lymphoblastic leukaemia, The Lancet, vol.371, issue.9617, pp.1030-1043, 2008. ,
DOI : 10.1016/S0140-6736(08)60457-2
Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10, Leukemia, vol.75, issue.4, pp.567-574312, 2010. ,
DOI : 10.1080/15476910802129661
Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia, Blood, vol.123, issue.24, pp.3739-3749, 2014. ,
DOI : 10.1182/blood-2014-01-547695
Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases, Leukemia, vol.89, issue.4, pp.806-807303, 2008. ,
DOI : 10.1002/cncr.23824
Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study, Haematologica, vol.100, issue.4, pp.128-131, 2015. ,
DOI : 10.3324/haematol.2014.120220
A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide., Journal of Clinical Oncology, vol.9, issue.3, pp.478-490, 1991. ,
DOI : 10.1200/JCO.1991.9.3.478
Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias., Journal of Clinical Oncology, vol.11, issue.2, pp.294-303, 1993. ,
DOI : 10.1200/JCO.1993.11.2.294
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias, Cancer Res, vol.55, issue.23, pp.5908-5910, 1995. ,
Preparation of alpha-emitting 213Bi- labeled antibody constructs for clinical use, J Nucl Med, vol.40, issue.10, pp.1722-1727, 1999. ,
Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti- CD33 antibodies: Pharmacokinetics, bioactivity, toxicity and chemistry, J Nucl Med, vol.40, issue.1, pp.166-176, 1999. ,
Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia, J Nucl Med, vol.40, issue.11, pp.1935-1946, 1999. ,
Sequential Cytarabine and ??-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia, Clinical Cancer Research, vol.16, issue.21, pp.5303-5311, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-0382
Tumor Therapy with Targeted Atomic Nanogenerators, Science, vol.294, issue.5546, pp.1537-1540, 2001. ,
DOI : 10.1126/science.1064126
Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML)., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.768, 2011. ,
DOI : 10.1200/jco.2011.29.15_suppl.6516
Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, pp.126-131 ,
DOI : 10.14694/EdBook_AM.2014.34.e126
Human homologue of murine T200 glycoprotein, Journal of Experimental Medicine, vol.152, issue.4, pp.842-852, 1980. ,
DOI : 10.1084/jem.152.4.842
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies, Cancer Res, vol.49, issue.17, pp.4906-4912, 1989. ,
Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model, Cancer Res, vol.52, issue.1, pp.89-94, 1992. ,
Phase I study of (131)I-anti- CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome, Blood, vol.94, issue.4, pp.1237-1247, 1999. ,
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission, Blood, vol.107, issue.5, pp.2184-2191, 2005. ,
DOI : 10.1182/blood-2005-06-2317
Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome, Blood, vol.114, issue.27, pp.5444-5453, 2009. ,
DOI : 10.1182/blood-2009-03-213298
Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation, Blood, vol.85, issue.4, pp.1122-1131, 1995. ,
Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome, Biology of Blood and Marrow Transplantation, vol.20, issue.9, pp.1363-1368, 2014. ,
DOI : 10.1016/j.bbmt.2014.05.014
Anti-CD45 Radioimmunotherapy with 90Y but Not 177Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model, PLoS ONE, vol.136, issue.12, 2014. ,
DOI : 10.1371/journal.pone.0113601.t001
Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model, Blood, vol.121, issue.18, pp.3759-3767, 2013. ,
DOI : 10.1182/blood-2012-11-467035
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy, Blood, vol.111, issue.4, pp.2261-2268, 2008. ,
DOI : 10.1182/blood-2007-06-097451
Antibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy, Journal of Clinical Oncology, vol.24, issue.5, pp.823-834, 2006. ,
DOI : 10.1200/JCO.2005.03.8471
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates, Blood, vol.114, issue.6, pp.1226-1235, 2009. ,
DOI : 10.1182/blood-2009-03-210344
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model, Blood, vol.118, issue.3, pp.703-711, 2011. ,
DOI : 10.1182/blood-2011-04-347039
Radioimmunoconjugates in acute leukemia treatment: the future is radiant, Bone Marrow Transplantation, vol.101, issue.12, pp.1021-1026, 2005. ,
DOI : 10.1038/sj.bmt.1705182
A comparison of the biodistribution and biokinetics of 99mTc-anti-CD66 mAb BW 250/183 and 99mTc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.5, pp.667-673, 2003. ,
DOI : 10.1007/s00259-002-1106-9
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study, British Journal of Haematology, vol.37, issue.4, pp.604-613, 2005. ,
DOI : 10.1182/blood-2003-03-0855
Radioimmunotherapy-based conditioning for hematopoietic cell transplantation in children with malignant and nonmalignant diseases, Blood, vol.117, issue.17, pp.4642-4650, 2011. ,
DOI : 10.1182/blood-2010-06-284349
Radioimmunotherapy with [188Re]-labelled anti-CD66 antibody in the conditioning for allogeneic stem cell transplantation for high-risk acute myeloid leukemia, International Journal of Hematology, vol.92, issue.4, pp.414-421, 2008. ,
DOI : 10.1007/s12185-008-0043-1
Erh??hte Nephrotoxizit??t bei Ganzk??rperbestrahlung und zus??tzlicher Radioimmuntherapie, Strahlentherapie und Onkologie, vol.179, issue.10, pp.702-707, 2003. ,
DOI : 10.1007/s00066-003-1090-4
Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation, J Nucl Med, vol.47, issue.2, pp.278-286, 2006. ,
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study, Blood, vol.98, issue.3, pp.565-572, 2001. ,
DOI : 10.1182/blood.V98.3.565
T cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation, British Journal of Haematology, vol.45, issue.Suppl, pp.910-917, 2010. ,
DOI : 10.1111/j.1365-2141.2009.08025.x
Reduced-intensity conditioning combined with (188)Rhenium radioimmunotherapy before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: The role of in vivo t cell depletion, Biol Blood Marrow Transplant, 2015. ,
Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy, PLOS ONE, vol.6, issue.2 ,
DOI : 10.1371/journal.pone.0127934.s004
124I-Anti-CD52 Dosimetry Before Radioimmunotherapy as Part of Conditioning for Stem Cell Transplantation in Acute Leukemia, Clinical Nuclear Medicine, vol.37, issue.4, pp.390-392, 2012. ,
DOI : 10.1097/RLU.0b013e3182443b64
B-ALL: proof of principle, European Journal of Haematology, vol.9, issue.6, pp.552-556, 2013. ,
DOI : 10.1111/ejh.12183
90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study, The Lancet Haematology, vol.2, issue.3, pp.108-117, 2015. ,
DOI : 10.1016/S2352-3026(15)00020-4
Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study, Journal of Clinical Oncology, vol.26, issue.22, pp.3756-3762, 2008. ,
DOI : 10.1200/JCO.2007.15.3528
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia, British Journal of Haematology, vol.120, issue.4, pp.504-509, 2014. ,
DOI : 10.1111/bjh.12778
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab, Molecular Immunology, vol.44, issue.6, pp.1331-1341, 2007. ,
DOI : 10.1016/j.molimm.2006.05.007
Consolidation Anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: A LYSA Phase II prospective trial ,